NCT05900908 2025-04-10
PATHWAyS
GT Medical Technologies, Inc.
Phase 4 Withdrawn
Clinical Trials
13 trialsNCT02201381 2022-07-18
METRICS
Health Clinics Limited
Phase 3 Withdrawn
NCT03868423 2022-02-18
Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers
Ohio State University Comprehensive Cancer Center
Phase 2 Withdrawn
NCT02567643 2022-01-11
Stereotactic Radiosurgery (SRS) for Multiple CNS Mets
The Cooper Health System
Phase NA Withdrawn
NCT01736722 2018-01-17
MRI-Guided LITT for Treatment Metastatic Brain Tumors
The Methodist Hospital Research Institute
Phase NA Withdrawn
NCT01736800 2017-09-19
Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors
The Methodist Hospital Research Institute
Phase 2 Withdrawn
NCT01174537 2015-06-11
New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma
Hadassah Medical Organization
Phase 1/2 Withdrawn
NCT00247403 2015-04-10
Safety Study of 2DG With Stereotactic Radiosurgery
University of Iowa
Phase 1 Withdrawn
NCT02000739 2014-07-14
GENIUS
Dartmouth-Hitchcock Medical Center
Phase 4 Withdrawn
NCT01169116 2014-02-04
Exclusive Hypofractionated Stereotactic Radiotherapy in Non-resectable Single Brain Metastasis
Barretos Cancer Hospital
Phase 2 Withdrawn
NCT01169129 2014-02-04
Surgery and Whole Brain Radiotherapy (RT) Versus Whole Brain Radiotherapy (RT) and Radiosurgery for 1-3 Resectable Brain Metastases
Barretos Cancer Hospital
Phase 3 Withdrawn
NCT00385398 2013-09-02
QOL-Stereotactic RadioSurgery, Temozolomide + Erlotinib-Rx of 1-3 Brain Metastases in NSCLC
Rutgers, The State University of New Jersey
Phase 2 Withdrawn
NCT00738335 2012-10-04
Stereotactic Radiosurgery and Erlotinib in Treating Patients With Non-Small Cell Lung Cancer and Brain Metastases
University of California, San Francisco
Phase 1 Withdrawn